Are OKT3 binding sites on T cells modulated or merely converted (blindfolded) by OKT3 during therapy?
Carreno
M
M
Department of Surgery, University of Miami School of Medicine, Florida 33101.
Miller
J
J
Esquenazi
V
V
Milgrom
M
M
Roth
D
D
Fuller
L
L
D000911:Antibodies, Monoclonal / Q000032:analysis / Q000627:therapeutic use*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis / Q000276:immunology*; D000954:Antigens, Surface / Q000276:immunology; D018801:CD2 Antigens; D017252:CD3 Complex; D006084:Graft Rejection; D006801:Humans; D016030:Kidney Transplantation; D008214:Lymphocytes / Q000276:immunology; D011863:Radioimmunoassay; D011948:Receptors, Antigen, T-Cell / Q000032:analysis / Q000276:immunology*; D011971:Receptors, Immunologic / Q000032:analysis / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte; D000954:Antigens, Surface; D018801:CD2 Antigens; D017252:CD3 Complex; D011948:Receptors, Antigen, T-Cell; D011971:Receptors, Immunologic